Pivotal Role of mTOR in Non-Skin Manifestations of Psoriasis

Joo, Ka; Karsulovic, Claudio; Sore, Milisa; Hojman, Lia

Publication:
Pivotal Role of mTOR in Non-Skin Manifestations of Psoriasis

dc.contributor.author	Joo, Ka
dc.contributor.author	Karsulovic, Claudio
dc.contributor.author	Sore, Milisa
dc.contributor.author	Hojman, Lia
dc.date.accessioned	2025-01-29T18:06:10Z
dc.date.available	2025-01-29T18:06:10Z
dc.date.issued	2024
dc.description.abstract	Psoriasis is a chronic inflammatory condition affecting 2% of the Western population. It includes diverse manifestations influenced by genetic predisposition, environmental factors, and immune status. The sustained activation of mTOR is a key element in psoriasis pathogenesis, leading to an uncontrolled proliferation of cytokines. Furthermore, mTOR activation has been linked with the transition from psoriasis to non-skin manifestations such as psoriatic arthritis and cardiovascular events. While therapies targeting pro-inflammatory cytokines have shown efficacy, additional pathways may offer therapeutic potential. The PI3K/Akt/mTOR pathway, known for its role in cell growth, proliferation, and metabolism, has emerged as a potential therapeutic target in psoriasis. This review explores the relevance of mTOR in psoriasis pathophysiology, focusing on its involvement in cutaneous and atheromatous plaque proliferation, psoriatic arthritis, and cardiovascular disease. The activation of mTOR promotes keratinocyte and synovial cell proliferation, contributing to plaque formation and joint inflammation. Moreover, mTOR activation may exacerbate the cardiovascular risk by promoting pro-inflammatory cytokine production and dysregulation lipid and glucose metabolism. The inhibition of mTOR has shown promise in preclinical studies, reducing skin inflammation and plaque proliferation. Furthermore, mTOR inhibition may mitigate cardiovascular risk by modulating cholesterol metabolism and attenuating atherosclerosis progression. Understanding the role of mTOR in psoriasis, psoriatic arthritis, and cardiovascular disease provides insight into the potential treatment avenues and sheds light on the complex interplay of the immune and metabolic pathways in these conditions.
dc.description.version	Versión Publicada
dc.identifier.citation	Joo K, Karsulovic C, Sore M, Hojman L. Pivotal Role of mTOR in Non-Skin Manifestations of Psoriasis. Int J Mol Sci. 2024 Jun 20;25(12):6778. doi: 10.3390/ijms25126778
dc.identifier.doi	https://doi.org/10.3390/ijms25126778
dc.identifier.uri	https://hdl.handle.net/11447/9741
dc.language.iso	en
dc.subject	Cardiovascular disease
dc.subject	mTOR pathway
dc.subject	Psoriasis
dc.title	Pivotal Role of mTOR in Non-Skin Manifestations of Psoriasis
dc.type	Article
dcterms.accessRights	Acceso Abierto
dcterms.source	International journal of molecular sciences
dspace.entity.type	Publication
relation.isAuthorOfPublication	6217431a-6b70-4594-9c87-e4ea4c6980dd
relation.isAuthorOfPublication.latestForDiscovery	6217431a-6b70-4594-9c87-e4ea4c6980dd